279 related articles for article (PubMed ID: 22356229)
1. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis.
Campanati A; Orciani M; Gorbi S; Regoli F; Di Primio R; Offidani A
Br J Dermatol; 2012 Jul; 167(1):68-76. PubMed ID: 22356229
[TBL] [Abstract][Full Text] [Related]
2. The mesenchymal stem cell profile in psoriasis.
Orciani M; Campanati A; Salvolini E; Lucarini G; Di Benedetto G; Offidani A; Di Primio R
Br J Dermatol; 2011 Sep; 165(3):585-92. PubMed ID: 21623755
[TBL] [Abstract][Full Text] [Related]
3. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments.
Seneschal J; Milpied B; Vergier B; Lepreux S; Schaeverbeke T; Taïeb A
Br J Dermatol; 2009 Nov; 161(5):1081-8. PubMed ID: 19681863
[TBL] [Abstract][Full Text] [Related]
4. Abnormalities in cytokine secretion from mesenchymal stem cells in psoriatic skin lesions.
Liu R; Yang Y; Yan X; Zhang K
Eur J Dermatol; 2013; 23(5):600-7. PubMed ID: 24135516
[TBL] [Abstract][Full Text] [Related]
5. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor antagonists in the therapy of psoriasis.
Mössner R; Schön MP; Reich K
Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
[TBL] [Abstract][Full Text] [Related]
8. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
Vender R
J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis.
Bosè F; Petti L; Diani M; Moscheni C; Molteni S; Altomare A; Rossi RL; Talarico D; Fontana R; Russo V; Altomare G; Reali E
Am J Pathol; 2013 Aug; 183(2):413-21. PubMed ID: 23731727
[TBL] [Abstract][Full Text] [Related]
10. Effects of TNF-alpha inhibitors on circulating Th17 cells in patients affected by severe psoriasis.
Piaserico S; Sandini E; Saldan A; Abate D
Drug Dev Res; 2014 Nov; 75 Suppl 1():S73-6. PubMed ID: 25381985
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
Chiu HY; Hsueh PR; Tsai TF
Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
[TBL] [Abstract][Full Text] [Related]
12. TNF-α inhibitors reduce the pathological Th
Campanati A; Orciani M; Lazzarini R; Ganzetti G; Consales V; Sorgentoni G; Di Primio R; Offidani A
Exp Dermatol; 2017 Apr; 26(4):319-324. PubMed ID: 27376466
[TBL] [Abstract][Full Text] [Related]
13. Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.
Ryan C; Kelleher J; Fagan MF; Rogers S; Collins P; Barker JN; Allen M; Hagan R; Renfro L; Kirby B
Clin Exp Dermatol; 2014 Jun; 39(4):519-24. PubMed ID: 24758522
[TBL] [Abstract][Full Text] [Related]
14. Innovative uses of tumor necrosis factor alpha inhibitors.
Mazza J; Rossi A; Weinberg JM
Dermatol Clin; 2010 Jul; 28(3):559-75. PubMed ID: 20510765
[TBL] [Abstract][Full Text] [Related]
15. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
Wang F; Smith N; Maier L; Xia W; Hammerberg C; Chubb H; Chen C; Riblett M; Johnston A; Gudjonsson JE; Helfrich Y; Kang S; Fisher GJ; Voorhees JJ
Br J Dermatol; 2012 Jul; 167(1):92-102. PubMed ID: 22458549
[TBL] [Abstract][Full Text] [Related]
16. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.
Capo A; Di Nicola M; Auriemma M; Piaserico S; Cuccurullo C; Santilli F; Davi G; Amerio P
Eur J Dermatol; 2014; 24(1):133-5. PubMed ID: 24589526
[No Abstract] [Full Text] [Related]
17. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
18. MCP-1 in psoriatic patients: effect of biological therapy.
Lembo S; Capasso R; Balato A; Cirillo T; Flora F; Zappia V; Balato N; Ingrosso D; Ayala F
J Dermatolog Treat; 2014 Feb; 25(1):83-6. PubMed ID: 23480385
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
20. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
Cho YT; Chen CH; Chiu HY; Tsai TF
J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
